PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma

Cited by (179)

Items 101–179 of 179

1. The Roles of Hypoxia-Inducible Factors and Non-Coding RNAs in Gastrointestinal Cancer
   Hyun‐Soo Cho, Tae‐Su Han, Keun Hur, Hyun Seung Ban · 2019 · Genes
2. Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer
   Lifang Shen, Shui‐Hong Zhou, Yu Lian Guo · 2020 · OncoTargets and Therapy
3. Metabolic Regulation of CD8 + T Cells: From Mechanism to Therapy
   Ying Yi Zheng, Xiaomin Wang, Min Huang · 2022 · Antioxidants and Redox Signaling
4. Immunosurveillance of cancer cell stress
   Seila Lorenzo‐Herrero, Christian Sordo‐Bahamonde, Segundo R. Gonzalez, Alejandro López‐Soto · 2019 · Cell Stress
5. LRRC19—A Bridge between Selenium Adjuvant Therapy and Renal Clear Cell Carcinoma: A Study Based on Datamining
   Yitong Zhang, Jiaxing Wang, Xiqing Liu · 2020 · Genes
6. Targeting apoptosis in clear cell renal cell carcinoma
   Adam Kowalewski, Jędrzej Borowczak, Mateusz Maniewski, Karol Gostomczyk, Dariusz Grzanka, Łukasz Szylberg · 2024 · Biomedicine & Pharmacotherapy
7. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
   Alessia Cimadamore, Francesco Massari, Matteo Santoni, Antonio Lopez-beltran B, Liang Cheng C, Marina Scarpelli, Rodolfo Montironi, Holger Moch · 2020 · Current Drug Targets
8. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma
   Viktoria Stühler, Steffen Rausch, Jan Moritz Maas, Arnulf Stenzl, Jens Bedke · 2021 · Expert Opinion on Biological Therapy
9. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma
   Authors Li Zhou, Xuezhou Wang, Wenwen Yu, Lili Yang, Feng Wei, Qian Sun, Yang Wang, Fan Kou, Ruifeng Dong, Xiubao Ren et al. · 2020 · Pathology - Research and Practice
10. BNIP3 Upregulation Characterizes Cancer Cell Subpopulation With Increased Fitness and Proliferation
    Yanyan Zhu, Bowang Chen, Junya Yan, Wendi Zhao, Pengli Dou, Na Sun, Yaokai Wang, Xiaoyun Huang · 2022 · Frontiers in Oncology
11. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma
    Jose Ignacio Lopez, Rafael Pulido, Charles Henderson Lawrie, J.C. Angulo · 2018 · Annals of Diagnostic Pathology
12. Histopathologische Diagnose und Prognose des Nierenzellkarzinoms im Kontext der WHO-Klassifikation 2016
    Annette Zimpfer, Ä. Glass, Heike Zettl, Matthias Maruschke, Oliver W. Hakenberg, Andreas Erbersdobler · 2019 · Der Urologe
13. Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer
    Vicky Smith, Dave Chi Hoo Lee, Mark Reardon, Rekaya Shabbir, Sudhakar Sahoo, Peter Hoskin, Ananya Choudhury, Tim Illidge, Catharine West · 2023 · International Journal of Molecular Sciences
14. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
    Noah T. Trac, Hyun Seok Oh, Leila Izzy Jones, Randy Caliliw, Shinji Ohtake, Brian M. Shuch, Eun Ji Chung · 2022 · Molecules
15. T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker
    Constantin N. Baxevanis, Angelos D. Gritzapis, Ioannis F. Voutsas, Panagiota Batsaki, Maria Goulielmaki, Maria Adamaki, Vassilios Zoumpourlis, Sotirios P. Fortis · 2022 · Cancers
16. Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis
    Liyan Yu, Xuemei Liang, Jianwei Wang, Guangxiang Ding, Jinhai Tang, Juan Xue, Xin Qi He, Jingxuan Ge, Xianzhang Jin, Zhiyi Yang et al. · 2023 · Genetics Research
17. Identification of Clinical and Tumor Microenvironment Characteristics of Hypoxia-Related Risk Signature in Lung Adenocarcinoma
    Zili Dai, Taisheng Liu, Guihong Liu, Zhen Deng, Peng Yu, Baiyao Wang, Bohong Cen, Liyi Guo, Jiän Zhang · 2021 · Frontiers in Molecular Biosciences
18. Angiogenic and immunological pathways in metastatic renal cell carcinoma: A counteracting paradigm or two faces of the same medal? The GIANUS Review
    Sergio Bracarda A, Camillo Porta, Roberto Sabbatini, Licia Rivoltini · 2018 · Critical Reviews in Oncology/Hematology
19. Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression
    Chao Zhang, Qinglong Yan, Jiang Li, Ying Jie Zhu, Yu Zhang · 2020 · ACS Applied Bio Materials
20. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)
    María Armesto, Maitane Márquez, María Arestin, Peio Errarte, Ane Rubio-Zulaika, Lorea Manterola, Jose Ignacio Lopez, Charles Henderson Lawrie · 2021 · Cancers
21. Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1α under Hypoxia
    Jiawen Yong, Sabine Gröger, Julia von Bremen, Joerg Meyle, Sabine Ruf · 2022 · Cells
22. Prognostic Modeling of Lung Adenocarcinoma Based on Hypoxia and Ferroptosis-Related Genes
    Chang Liu, Yan-Qin Ruan, Laihao Qu, Zhenhua Li, Chao Xie, Ya-Qiang Pan, Hao-Fei Li, Dingbiao Li · 2022 · Journal of Oncology
23. Overcoming current challenges to T-cell receptor therapy via metabolic targeting to increase antitumor efficacy, durability, and tolerability
    Wendy Mao · 2022 · Frontiers in Immunology
24. Retracted Article: Oleuropein inhibits esophageal cancer through hypoxic suppression of BTG3 mRNA
    Fengli Zhang, Mei Zhang · 2019 · Food & Function · Retracted
25. Correlation of Systemic Inflammation Parameters and Serum SLFN11 in Small Cell Lung Cancer—A Prospective Pilot Study
    Ivana Simić, Azra Guzonjić, Jelena Kotur Stevuljević, Vesna Ćeriman Krstić, Natalija Samardžić, Katarina Savić Vujović, Dragana M. Jovanović · 2024 · Biomedicines
26. Long Non-Coding RNAs in Drug Resistance of Gastric Cancer: Complex Mechanisms and Potential Clinical Applications
    Xiangyu Meng, Xiao Bai, Angting Ke, Kaiqiang Li, Yun Lei, Siqi Ding, Dong‐Qiu Dai · 2024 · Biomolecules
27. Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
    Renate Pichler, Isabel Heidegger · 2017 · memo - Magazine of European Medical Oncology
28. Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
    Doo-Won Song, Woong‐Bin Ro, Hee‐Myung Park · 2021 · Journal of Veterinary Science
29. Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment
    Faiqa Mudassar, Han M. Shen, Kristina M. Cook, Eric K.C. Hau · 2022 · Journal of Medical Imaging and Radiation Oncology
30. PD-L1, a Potential Immunomodulator Linking Immunology and Orthodontically Induced Inflammatory Root Resorption (OIIRR): Friend or Foe?
    Jiawen Yong, Sabine Gröger, Julia von Bremen, Joerg Meyle, Sabine Ruf · 2022 · International Journal of Molecular Sciences
31. The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1
    Lifang Shen, Zi-Ming Fu, Shui‐Hong Zhou · 2023 · Japanese Journal of Radiology
32. The Current State of Immune Checkpoint Inhibitors in the First-Line Treatment of Renal Cancer
    Elie Rassy, Rita‐Maria Khoury‐Abboud, Nathalie Ibrahim, Tarek Assi, Fouad Y. Aoun, Joseph Gergi Kattan · 2018 · Immunotherapy
33. Integrated Analysis Of Immunotherapy Treated Clear Cell Renal Cell Carcinomas: An Exploratory Study
    Bettina Sobottka, Ronny Nienhold, Marta Nowak, Juergen Hench, Pirmin Haeuptle, Angela Frank, Melanie Sachs, Abdullah Kahraman, Holger Moch, Viktor H. Koelzer et al. · 2021 · Journal of Immunotherapy
34. [68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC
    Longxiyu Meng, Shun Zhang, Jie Gao, Qinfeng Xu, Yao Shi Fu, Yihua Zhou, Feng Wang, Hongqian Guo · 2022 · European Radiology
35. The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4
    Sasan Parvini, Jamal Majidpoor, Keywan Mortezaee · 2023 · Pathology - Research and Practice
36. Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer
    Kimihiro Shimizu, Kyoichi Kaira, Tetsuya Higuchi, Takeshi Hisada, Takehiko Yokobori, Tetsunari Oyama, Takayuki Asao, Yoshito Tsushima, Ken Shirabe · 2019 · Molecular Imaging and Biology
37. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells
    Dongwei Huang, Xueni Wang, Yunfeng Qian, Jun Wu, Binzhuan Chen, Deming Zhang, Fengying Dong, Yongqiang Li · 2023 · Cellular Immunology
38. Immunorthodontics: Role of HIF-1α in the Regulation of (Peptidoglycan-Induced) PD-L1 Expression in Cementoblasts under Compressive Force
    Jiawen Yong, Sabine Gröger, Joerg Meyle, Sabine Ruf · 2022 · International Journal of Molecular Sciences
39. Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages
    Xin Liu, Zhenke Li, Jinxing Sun, Zhijie Zhang, Weiguo Li · 2023 · BMC Cancer
40. Renal cell carcinoma pathology in 2021: ‘new need for renal cancer immune profiling’
    Bettina Sobottka, Anja Lorch, Karīna Siliņa, Maries F. van den Broek, Holger Moch · 2021 · Current Opinion in Urology
41. Immunotargeting and Personalized Therapies in Genitourinary Cancers
    Roberta Mazzucchelli A, Silvia Gasparrini, Andrea Benedetto Galosi, Francesco Massari, Chiara Ciccarese, Marina Scarpelli, Antonio Lopez-beltran B, Liang Cheng C, Rodolfo Montironi · 2016 · Future Oncology
42. Renal cell carcinoma organoids for precision medicine: bridging the gap between models and patients
    Jian Gao, Huijiu Luo, Shiyu Wang, Chao Zhou, Zhenhao Li, Chea Kimhoy, Guobiao Liang, Shulian Chen · 2025 · Journal of Translational Medicine
43. Optimization of immunotherapy-based combinations for metastatic renal cell carcinoma: A network meta-analysis
    Sohyeon Park, Kalynn Park, Chaeyoon Kim, Sandy Jeong Rhie · 2025 · Critical Reviews in Oncology/Hematology
44. The Efficacy of Radiation is Enhanced by Metformin and Hyperthermia Alone or Combined Against FSaII Fibrosarcoma in C3H Mice
    Hyun-Kyung Kim, Dohyeon Kim, Wonwoo Kim, Eunji Kim, Won Il Jang, Mi‐Sook Kim · 2022 · Radiation Research
45. PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule
    Domenic Vital, David Holzmann, Gerhard Frank Huber, Holger Moch, Grégoire B. Morand, Kristian Ikenberg · 2018 · Rhinology Journal
46. HIF Pathways in Clear Cell Renal Cancer
    Olivia Lombardi, David Robert Mole · 2021 · IntechOpen eBooks
47. Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer
    Hongmei Dai, Xiafei Hong, Dan Huang, Huanwen Wu, Xianze Wang, Hao Chen, Rui Jiang, Wenyan Chen, Yupei Zhao, Wenming Wu · 2021 · Journal of Pancreatology
48. Siah2 Inhibitor and the Metabolic Antagonist Oxamate Retard Colon Cancer Progression and Downregulate PD1 Expression
    Sherin Zakaria, Samar Elsebaey, Shady Allam, Walied Abdo, Alaa E. El‐Sisi · 2023 · Recent Patents on Anti-Cancer Drug Discovery
49. BMP9‐induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus‐associated hepatocellular carcinoma
    Yulong Han, Qiuzhong Pan, Zhixing Guo, Yufei Du, Yaojun Zhang, Yingying Liu, Jingjing Zhao, Jinfeng Xu, Jieying Yang, Dijun Ouyang et al. · 2023 · Clinical and Translational Medicine
50. Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
    Meshach Asare-Werehene, Arvin Zaker, Shivanshi Tripathi, Laudine Communal, Eurı́dice Carmona, Anne‐Marie Mes‐Masson, Benjamin K. Tsang, Arvind Singh Mer · 2025 · Frontiers in Immunology
51. Extra villous trophoblast-derived PDL1 can ameliorate macrophage inflammation and promote immune adaptation associated with preeclampsia
    Yutong Cui, Suwen Wu, Ketong Liu, Huanqiang Zhao, Bo Ma, Lili Gong, Qiongjie Zhou, Xiaotian Li · 2023 · Journal of Reproductive Immunology
52. Harnessing the Power of Nanomaterials to Alleviate Tumor Hypoxia in Favor of Cancer Therapy
    Hamid Rashidzadeh, Faezeh Mozafari, Mohammadreza Ghaffarlou, Murat Barsbay, Ali Ramazani, Morteza Abazari, Mohammad-Amin Rahmati, Hafeez Anwar, S. K. Sharma, Hossein Danafar · 2022 · Nanomedicine and nanotoxicology
53. Exploring the dynamics of Programmed Death-Ligand 1 in canine lymphoma: unraveling mRNA amount, surface membrane expression and plasmatic levels
    Alessandra Ubiali, Luiza Cesar Conti, Paola Dall’Ara, Raffaella De Maria, Luca Aresu, Pierangelo Moretti, Federica Sini, Fulvio Riondato, Damiano Stefanello, S. Comazzi et al. · 2024 · Frontiers in Veterinary Science
54. Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
    Л. В. Спирина, Zahar A. Yurmazov, Evgeny A. Usynin, И. В. Кондакова, Ekaterine Ladutko, Е. Л. Чойнзонов · 2021 · Current Issues in Molecular Biology
55. Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
    Rustem Airatovich Gafanov, A. G. Dzidzaria, Кравцов Игорь Борисович, С. В. Фастовец · 2020 · Cancer Urology
56. RNA Sequencing Reveals Alterations and Similarities in Cell Metabolism, Hypoxia and Immune Evasion in Primary Cell Cultures of Clear Cell Renal Cell Carcinoma
    Adrian Georg Simon, Laura Kristin Esser, Jörg Ellinger, Manuel Ritter, Glen Kristiansen, Michael H. Muders, Thomas Mayr, Marieta Ioana Toma · 2022 · Frontiers in Oncology
57. Expression of Programmed Death-1 Ligand in Renal Cell Carcinoma and Its Relationship with Pathologic Findings and Disease-Free Survival
    Hedieh Moradi Tabriz, Elham Nazar, Narges Akhlaghi, Arezoo Eftekhar Javadi · 2022 · Nephro-Urology Monthly
58. Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging
    Renee L. Tran, Xiaofei Liang, Jorge de la Cerda, F William Schuler, Marty D. Pagel · 2025 · Scientific Reports
59. Clinical Trials for Specific Renal Cancer Subtypes—The Time Will Come!
    Niels J. Rupp, Rodolfo Montironi, Axel Mischo, Holger Moch · 2017 · European Urology Supplements
60. The Role of Pd-L1 on Tumor Cells in Host Immune System Escape and Tumor Immunotherapy by Pd-L1 Blockade; Immune Checkpoint Blockade in Cancer Immunotherapy
    Mehmet Eraslan · 2021 · ACTA SCIENTIFIC MICROBIOLOGY
61. Non-coding RNAs’ pivotal importance in modulation of cancer sensitivity to Topotecan: a systematic review
    Seyed Mostafa Rahimi, Abouzar Bagheri · 2025 · Medical Oncology
62. Expression of PD-L1 and PD-L2 and Their Association with IFN-γ/STAT1/STAT3 Signaling in Human Clear Cell Renal Cell Carcinoma (ccRCC)
    Gábor Kónya, Ali Shammas, Erzsébet Szabó, Róbert Tupicza, Seyed Behrad Piran, Krisztián Szegedi, Anna Vass, Éva Juhász, József Király, Balázs Dezsö et al. · 2026 · Journal of Clinical Medicine
63. Tumor-Induced Metabolism and T Cells Located in Tumor Environment
    Sara Iranparast, Sanaz Tayebi, Fatemeh Ahmadpour, Bahman Yousefi · 2020 · Current Cancer Drug Targets
64. Pleiotropic Action of Selenium in the Prevention and Treatment of Cancer, and Related Diseases
    Youcef M. Rustum · 2019 · MDPI eBooks
65. VHL, BAP1, PBRM1, SETD2 Expression in Clear Cell Renal Carcinoma, Association With PD-1, PD-L1, PD-L2 mRNA Level
    Л. В. Спирина, Zahar Yurnazov, Evgeny A. Usynin, И. В. Кондакова, Ekaterina Ladutko, Е. Л. Чойнзонов · 2021 · Preprints.org
66. The Role of 18F-FDG-PET as Therapeutic Monitoring in Patients with Lung Cancer
    Kyoichi Kaira · 2020 · Springer eBooks
67. The role of GLUT-1 in upregulation of PD-L1 expression after radiotherapy and PD-L1 is associated with a favourable overall survival in hypopharyngeal cancer
    Lifang Shen, Shuihong Zhou, Yu Guo · 2020
68. Cancer therapeutics and gut microflora
    Shruti Ahlawat, Asha Asha, Krishna Kant Sharma · 2022 · Elsevier eBooks
69. Relationships of 18F-FDG PET with tumor microenvironment immunotypes, especially PD-L1 and CD15 expression, and prognosis in oral squamous cell carcinoma
    Mai Seki, Takaaki Sano, Masaru Ogawa, Satoshi Yokoo, Tetsunari Oyama · 2023 · The Egyptian Journal of Radiology and Nuclear Medicine
70. Immune System, Redox Signaling, and Cancer Immunity
    Mohinder Pal Bansal · 2023 · Springer eBooks
71. Correlation between PD-L1 and Ki-67 Expression at various T-stage Clear Cell Renal Cell Carcinomas
    Anny Setijo Rahaju, Alphania Rahniayu, Etty Hary Kusumastuti, Priangga Adi Wiratama, Pamela Kusumadewi Putri Thaib, Mimi Takaria · 2024 · Research Journal of Pharmacy and Technology
72. Diagnostic, prognostic, and therapeutic biomarkers of ovarian cancer
    Meshach Asare-Werehene, Hideaki Tsuyoshi, Elaine Yuen Phin Lee, Keith Wan-Hang Chiu, Siew‐Fei Ngu, Hys Ngan, Karen K. L. Chan, Yoshio Yoshida, Benjamin K. Tsang · 2024 · Elsevier eBooks
73. Critères d’évaluation de la TEP au 18F-FDG au cours de l’immunothérapie
    D. Hamdan, E. Anjorand, G. Bousquet, M. Soussan · 2024 · Médecine Nucléaire
74. Acute remote ischemic conditioning enhances (CD3+)- but not (FoxP3+)-T-cell invasion in the tumor center and increases IL 17 and TNF-alpha expression in a murine melanoma model
    Katarzyna Rachunek, Sabrina Krauß, Adrien Daigeler, Constantin Adams, Franziska Eckert, Katrin Ganser, Irene González-Menéndez, Leticia Quintanilla‐Martínez, Jonas Kolbenschlag · 2024 · Frontiers in Immunology
75. Additional file 1 of Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages
    Liu, Xin, Zhenke Li, Sun, Jinxing, Zhang, Zhijie, Li, Weiguo · 2023 · Figshare
76. Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies
    Xiaoxuan Duan, Luqi Yan, Yingfei Wang, Xiaoshuo Dai, Chengjuan Zhang, Jing Lu · 2026 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
77. Impact du ciblage du domaine de liaison de HIF-1α avec HIF-1β sur le paysage immunitaire du mélanome
    Audrey Lequeux · 2020 · theses.fr (ABES)
78. A pH and glucose dual-responsive nanocatalyst system for targeted tumor therapy, microenvironment reprogramming, and synergistic immune checkpoint blockade
    Chunyu Qu, Yuanjin Sun, Kailei Liu, Ping Gan, Xichan Li, Yue Pan, Hui Zhang, Zhiqiang Wang, Guanghui Tan, Yingxue Jin · 2026 · Journal of Colloid and Interface Science
79. Envafolimab – novel anti-PD-1/PD-L1 antibody in cancer treatment
    Mateusz Kciuk, Damian Kołat, Katarzyna Wanke, Renata Kontek · 2026 · Frontiers in Immunology